E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium
- Authors
- Horne, Hisani N.; Oh, Hannah; Sherman, Mark E.; Palakal, Maya; Hewitt, Stephen M.; Schmidt, Marjanka K.; Milne, Roger L.; Hardisson, David; Benitez, Javier; Blomqvist, Carl; Bolla, Manjeet K.; Brenner, Hermann; Chang-Claude, Jenny; Cora, Renata; Couch, Fergus J.; Cuk, Katarina; Devilee, Peter; Easton, Douglas F.; Eccles, Diana M.; Eilber, Ursula; Hartikainen, Jaana M.; Heikkila, Paivi; Holleczek, Bernd; Hooning, Maartje J.; Jones, Michael; Keeman, Renske; Mannermaa, Arto; Martens, John W. M.; Muranen, Taru A.; Nevanlinna, Heli; Olson, Janet E.; Orr, Nick; Perez, Jose I. A.; Pharoah, Paul D. P.; Ruddy, Kathryn J.; Saum, Kai-Uwe; Schoemaker, Minouk J.; Seynaeve, Caroline; Sironen, Reijo; Smit, Vincent T. H. B. M.; Swerdlow, Anthony J.; Tengstrom, Maria; Thomas, Abigail S.; Timmermans, A. Mieke; Tollenaar, Rob A. E. M.; Troester, Melissa A.; van Asperen, Christi J.; van Deurzen, Carolien H. M.; Van Leeuwen, Flora F.; Van'tVeer, Laura J.; Garcia-Closas, Montserrat; Figueroa, Jonine D.
- Issue Date
- 26-4월-2018
- Publisher
- NATURE PUBLISHING GROUP
- Citation
- SCIENTIFIC REPORTS, v.8
- Indexed
- SCIE
SCOPUS
- Journal Title
- SCIENTIFIC REPORTS
- Volume
- 8
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/76092
- DOI
- 10.1038/s41598-018-23733-4
- ISSN
- 2045-2322
- Abstract
- E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, > 2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Public Health Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.